- 110428-56-3Pregn-4-ene-3,11,20-trione,21-amino-17-hydroxy-, hydrochloride (9CI)
- 110-42-9Decanoic acid, methylester
- 110429-35-1Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate(2:2:1), (3S,4R)-
- 110429-36-2N-Methylparoxetine
- 110-43-02-Heptanone
- 110431-65-71,2,3,4,5,6-Benzenehexathiol,sodium salt (1:6)
- 11043-91-7Trisporic acid
- 110-44-1Sorbic acid
- 110-45-21-Butanol, 3-methyl-,1-formate
- 110453-78-61-Octanol, 6-methyl-,(6S)-
Hot Products
- 55837-20-2Halofuginone
- 5337-93-91-Propanone,1-(4-methylphenyl)-
- 1116-76-31-Octanamine,N,N-dioctyl-
- 50-01-1Guanidine hydrochloride
- 121-69-7N,N-Dimethylaniline
- 600-21-5N-Methyl-DL-alanine
- 9002-18-0Agar
- 9000-71-9Casein
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
gamma-Oryzanol |
EINECS | 244-285-1 |
| CAS No. | 11042-64-1 | Density | 1.1 g/cm3 |
| PSA | 55.76000 | LogP | 10.14740 |
| Solubility | soluble in acetone, chloroform; sparingly soluble in ethanol and n-heptane; insoluble in water | Melting Point |
135-137 ºC |
| Formula | C40H58O4 | Boiling Point | 663.2 ºC at 760 mmHg |
| Molecular Weight | 602.98 | Flash Point | 193.8 ºC |
| Transport Information | N/A | Appearance | White or white crystalline powder, odourless |
| Safety | Risk Codes | N/A | |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Gamma oryzanol;Oryzanol;CCRIS 4251;Gammariza;HI-Z;OZ;Oliver;UNII-SST9XCL51M;9,19-Cyclo-9beta-lanost-24-en-3beta-ol 4-hydroxy-3-methoxycinamate; |
gamma-Oryzanol Specification
The γ-Oryzanol, with the CAS registry number 11042-64-1, has the product categories which are including Aromatic Esters; Nutritional Supplements. Besides, it is usually applied in curing many diseases, such as periodic psychosis, premenstrual tension, women's Menopause Syndrome, vascular headache, and dysfunction of autonomic nervoussystem.
The characteristics of this chemical are as below: (1)ACD/LogP: 12.85; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): 12.85; (4)ACD/LogD (pH 7.4): 12.85; (5)#H bond acceptors: 4; (6)#H bond donors: 1; (7)#Freely Rotating Bonds: 10; (8)Polar Surface Area: 44.76; (9)Index of Refraction: 1.569; (10)Molar Refractivity: 178.62 cm3; (11)Molar Volume: 544.6 cm3; (12)Polarizability: 70.81×10-24 cm3; (13)Surface Tension: 46.2 dyne/cm; (14)Density: 1.1 g/cm3; (15)Flash Point: 193.8 °C; (16)Enthalpy of Vaporization: 101.08 kJ/mol; (17)Boiling Point: 663.2 °C at 760 mmHg; (18)Vapour Pressure: 3.38E-18 mmHg at 25°C; (19)Exact Mass: 602.43351; (20)MonoIsotopic Mass: 602.43351; (21)Topological Polar Surface Area: 55.8; (22)Heavy Atom Count: 44; (23)Complexity: 1150.
In adddition, you could convert the following datas into the molecular structure:
(1)Canonical SMILES: CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)OC(=O)C=CC6=CC(=C(C=C6)O)OC)C)C
(2)Isomeric SMILES: C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C
(3)InChI: InChI=1S/C40H58O4/c1-26(2)10-9-11-27(3)29-18-20-38(7)33-16-15-32-36(4,5)34(19-21-39(32)25-40(33,39)23-22-37(29,38)6)44-35(42)17-13-28-12-14-30(41)31(24-28)43-8/h10,12-14,17,24,27,29,32-34,41H,9,11,15-16,18-23,25H2,1-8H3/b17-13+/t27-,29-,32+,33+,34+,37-,38+,39-,40+/m1/s1
(4)InChIKey: FODTZLFLDFKIQH-FSVGXZBPSA-N
Below are the toxicity information of this chemical:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD | oral | > 5gm/kg (5000mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 6, Pg. 2401, 1978. | |
| guinea pig | LD50 | skin | 100mg/kg (100mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 7, Pg. 1295, 1979. | |
| mouse | LD | intramuscular | > 500mg/kg (500mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 2781, 1973. | |
| mouse | LD | intraperitoneal | > 10gm/kg (10000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 2781, 1973. |
| mouse | LD | subcutaneous | > 2500mg/kg (2500mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 2781, 1973. | |
| mouse | LD50 | intravenous | 811mg/kg (811mg/kg) | Drugs in Japan Vol. -, Pg. 297, 1995. | |
| mouse | LD50 | oral | > 25gm/kg (25000mg/kg) | Drugs in Japan Vol. -, Pg. 297, 1995. | |
| rabbit | LD | oral | > 5gm/kg (5000mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 6, Pg. 2401, 1978. |
| rabbit | LD | subcutaneous | > 2500mg/kg (2500mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 6, Pg. 2401, 1978. | |
| rat | LD | intramuscular | > 500mg/kg (500mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 2781, 1973. | |
| rat | LD | subcutaneous | > 1gm/kg (1000mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 2781, 1973. | |
| rat | LD50 | intravenous | 382mg/kg (382mg/kg) | Drugs in Japan Vol. -, Pg. 297, 1995. | |
| rat | LD50 | oral | > 25gm/kg (25000mg/kg) | Drugs in Japan Vol. -, Pg. 297, 1995. | |
| rat | LD50 | skin | 100mg/kg (100mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 7, Pg. 1295, 1979. | |
| rat | LDLo | intraperitoneal | 1250mg/kg (1250mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 2781, 1973. |
What can I do for you?
Get Best Price
